multiple sclerosis

positive negative up down good bad mixed
Biotech

Sanofi lifts lid on data behind tolebrutinib’s mixed MS studies

Sanofi linked the BTK inhibitor to a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive MS.
Nick Paul Taylor Sep 20, 2024 7:07am
plan B fail reroute road path trail miss

Sanofi's tolebrutinib fails 2 of 3 late-stage MS trials

Sep 2, 2024 1:00am
brain amyloid alzheimers strings detailed web complicated thought

Siemens Healthineers nets CE Mark for MS relapse risk blood test

Jun 17, 2024 11:30am
IPO initial public offering Wall Street

Contineum lowers expectations for $110M IPO

Apr 5, 2024 7:00am
Graphic image of the letters IPO in white in front of a yellow background

J&J-allied bio files IPO to take fight to BMS, Roche and more

Mar 18, 2024 7:15am
end of the road road block shut down closed blocked

Merck KGaA drops evobrutinib in wake of double phase 3 fail

Mar 7, 2024 9:54am